Ken Griffin Pharma Cyte Biotech, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$1.95 - $2.48 $5,460 - $6,944	-2,800 Reduced 34.15%	5,400 $12,000
Q4 2023 Feb 14, 2024	BUY	$2.01 - $2.34 $9,647 - $11,232	4,800 Added 141.18%	8,200 $17,000
Q3 2023 Nov 14, 2023	SELL	$2.09 - $2.89 $2,090 - $2,890	-1,000 Reduced 22.73%	3,400 $7,000
Q2 2023 Aug 14, 2023	BUY	$2.74 - $3.18 $2,740 - $3,180	1,000 Added 29.41%	4,400 $12,000
Q1 2023 May 15, 2023	SELL	$2.83 - $3.03 $89,428 - $95,748	-31,600 Reduced 90.29%	3,400 $9,000
Q4 2022 Feb 14, 2023	SELL	$2.39 - $3.07 $8,604 - $11,052	-3,600 Reduced 9.33%	35,000 $102,000
Q3 2022 Nov 14, 2022	BUY	$2.24 - $2.85 $48,832 - $62,130	21,800 Added 129.76%	38,600 $93,000

1.12M

Ticker PMCB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,750,100
Market Cap $33M
Description
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.